Literature DB >> 23391517

Chromosome 5q deletion is extremely rare in patients with myelofibrosis.

Koichi Takahashi1, Jorge Cortes, Sherry Pierce, Lynne Abruzzo, Hagop Kantarjian, Srdan Verstovsek.   

Abstract

Chromosome 5q deletion can be found in rare cases of myelofibrosis (MF) but the incidence, clinical significance and response to therapies are not well studied. We retrospectively reviewed charts of 939 patients with MF and identified 8 patients [0.8%] who carried 5q deletion. Of the 8, seven had complex cytogenetic abnormalities and one had additional clone with different cytogenetic abnormality. All 8 had significant three-lineage pancytopenia. Three patients took lenalidomide and one (patient with 5q-clone) achieved long-lasting hematologic response. Two patients responded to JAK2 inhibitor therapy. MF patients with 5q deletion often have complex karyotype and poor outcome.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23391517      PMCID: PMC4408989          DOI: 10.1016/j.leukres.2013.01.003

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  28 in total

1.  Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.

Authors:  A Tefferi; T L Lasho; R A Mesa; A Pardanani; R P Ketterling; C A Hanson
Journal:  Leukemia       Date:  2007-04-26       Impact factor: 11.528

2.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Authors:  Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; James S Wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

3.  International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.

Authors:  Kebede Hussein; Animesh D Pardanani; Daniel L Van Dyke; Curtis A Hanson; Ayalew Tefferi
Journal:  Blood       Date:  2009-11-09       Impact factor: 22.113

4.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

5.  Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.

Authors:  Rafael Santana-Davila; Ayalew Tefferi; Shernan G Holtan; Rhett P Ketterling; Gordon W Dewald; Ryan A Knudson; David P Steensma; Dong Chen; James D Hoyer; Curtis A Hanson
Journal:  Leuk Res       Date:  2008-06-09       Impact factor: 3.156

6.  The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.

Authors:  Constantine S Tam; Lynne V Abruzzo; Katherine I Lin; Jorge Cortes; Alice Lynn; Michael J Keating; Deborah A Thomas; Sherry Pierce; Hagop Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

7.  Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution.

Authors:  Rafael Santana-Davila; Shernan G Holtan; Gordon W Dewald; Rhett P Ketterling; Ryan A Knudson; Curtis A Hanson; David P Steensma; Ayalew Tefferi
Journal:  Leuk Res       Date:  2007-08-20       Impact factor: 3.156

8.  The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.

Authors:  Tomonori Hidaka; Kotaro Shide; Haruko Shimoda; Takurou Kameda; Keiko Toyama; Keiko Katayose; Youko Kubuki; Kenji Nagata; Katsuto Takenaka; Koichi Akashi; Takashi Okamura; Yoshiyuki Niho; Hideaki Mizoguchi; Mitsuhiro Omine; Keiya Ozawa; Mine Harada; Kazuya Shimoda
Journal:  Eur J Haematol       Date:  2009-06-15       Impact factor: 2.997

9.  Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.

Authors:  Alfonso Quintás-Cardama; Hagop M Kantarjian; Taghi Manshouri; Deborah Thomas; Jorge Cortes; Farhad Ravandi; Guillermo Garcia-Manero; Alessandra Ferrajoli; Carlos Bueso-Ramos; Srdan Verstovsek
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

10.  Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.

Authors:  Benjamin L Ebert; Jennifer Pretz; Jocelyn Bosco; Cindy Y Chang; Pablo Tamayo; Naomi Galili; Azra Raza; David E Root; Eyal Attar; Steven R Ellis; Todd R Golub
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962

View more
  6 in total

1.  Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.

Authors:  Koichi Takahashi; Naveen Pemmaraju; Paolo Strati; Graciela Nogueras-Gonzalez; Jing Ning; Carlos Bueso-Ramos; Rajyalakshmi Luthra; Sherry Pierce; Jorge Cortes; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Blood       Date:  2013-07-29       Impact factor: 22.113

Review 2.  Management of Myelofibrosis-Related Cytopenias.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 3.  Myelofibrosis: an update on drug therapy in 2016.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Expert Opin Pharmacother       Date:  2016-11-07       Impact factor: 3.889

4.  Thalidomide treatment in a myelofibrosis patient with leukemia transformation.

Authors:  Wei-Han Huang; Ming-Shing Li; Sung-Chao Chu; Tso-Fu Wang; Ruey-Ho Kao; Yi-Feng Wu
Journal:  Int J Hematol       Date:  2013-12-04       Impact factor: 2.490

5.  Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure.

Authors:  Ahmad Alhuraiji; Kiran Naqvi; Yang O Huh; Coty Ho; Srdan Verstovsek; Prithviraj Bose
Journal:  Clin Case Rep       Date:  2017-12-06

Review 6.  Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy.

Authors:  Pellegrino Musto; Vittorio Simeon; Roberto Guariglia; Gabriella Bianchino; Vitina Grieco; Filomena Nozza; Francesco La Rocca; Gioacchino Marziano; Anna Vittoria Lalinga; Emiliano Fabiani; Maria Teresa Voso; Patrizia Scaravaglio; Cristina Mecucci; Giovanni D'Arena
Journal:  Onco Targets Ther       Date:  2014-06-13       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.